Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K

Bone17 Oct 2011Cited by 69 (Europe PMC)

PMID22015818DOI10.1016/j.bone.2011.10.002PepBankPUB-22015818

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, trabecular volumetric BMD change differed significantly between teriparatide and alendronate, with an increase after teriparatide.
In plain wordsTrabecular bone density increased after teriparatide, with a significant difference from alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular volumetric BMD change versus alendronate
Study
n = 48
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · 18 monthsAs given in this study (human).
Measurements
Trabecular volumetric BMD change
4.6%
teriparatide group versus baseline at 18 months
Source sentences
Summary
The only significant between-treatment difference was in the change in trabecular volumetric BMD (p<0.005);
2 context sentences(design, population, supporting numbers)
Summary · context
At 18 months, we found in the women treated with teriparatide that trabecular volumetric BMD increased versus baseline (+4.6%, p<0.001),
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
Report a problemFND-2201581806
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, peripheral volumetric BMD changes did not differ significantly between teriparatide and alendronate.
In plain wordsPeripheral bone density changes did not differ significantly between teriparatide and alendronate in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePeripheral volumetric BMD change versus alendronate
Study
n = 48
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · 18 monthsAs given in this study (human).
Source sentences
Summary
The only significant between-treatment difference was in the change in trabecular volumetric BMD (p<0.005);
2 context sentences(design, population, supporting numbers)
Summary · context
The QCT scans, obtained at baseline, 6, and 18 months, were analyzed for volumetric bone mineral density (BMD) of trabecular bone, the peripheral bone (defined as all the cortical bone plus any endosteal trabecular bone within 3 mm of the periosteal surface), and the integral bone (both trabecular a…
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
Report a problemFND-2201581808
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, integral volumetric BMD changes did not differ significantly between teriparatide and alendronate.
In plain wordsOverall bone density changes did not differ significantly between teriparatide and alendronate in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeIntegral volumetric BMD change versus alendronate
Study
n = 48
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · 18 monthsAs given in this study (human).
Source sentences
Summary
The only significant between-treatment difference was in the change in trabecular volumetric BMD (p<0.005);
2 context sentences(design, population, supporting numbers)
Summary · context
The QCT scans, obtained at baseline, 6, and 18 months, were analyzed for volumetric bone mineral density (BMD) of trabecular bone, the peripheral bone (defined as all the cortical bone plus any endosteal trabecular bone within 3 mm of the periosteal surface), and the integral bone (both trabecular a…
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
Report a problemFND-2201581809
04HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, teriparatide increased trabecular volumetric BMD versus baseline.
In plain wordsTeriparatide increased trabecular bone density compared with baseline in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular volumetric BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · 18 monthsAs given in this study (human).
Measurements
BMD change
4.6%
teriparatide versus baseline
Source sentences
Summary
At 18 months, we found in the women treated with teriparatide that trabecular volumetric BMD increased versus baseline (+4.6%, p<0.001),
1 context sentence(design, population, supporting numbers)
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
Report a problemFND-2201581801
05HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, teriparatide decreased peripheral volumetric BMD versus baseline.
In plain wordsTeriparatide decreased peripheral bone density compared with baseline in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePeripheral volumetric BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · 18 monthsAs given in this study (human).
Measurements
BMD change
−1.1%
teriparatide versus baseline
Source sentences
Summary
peripheral volumetric BMD decreased (-1.1%, p<0.05),
1 context sentence(design, population, supporting numbers)
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
Report a problemFND-2201581802
06HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, integral volumetric BMD did not significantly change after teriparatide versus baseline.
In plain wordsOverall bone density did not significantly change after teriparatide compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeIntegral volumetric BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · 18 monthsAs given in this study (human).
Measurements
BMD change
1%
teriparatide versus baseline
Source sentences
Summary
integral volumetric BMD (+1.0%, p=0.38) and femoral strength (+5.4%, p=0.06) did not change significantly,
1 context sentence(design, population, supporting numbers)
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
Report a problemFND-2201581803

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

07Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoEfficacy outcome
In scan-based simulations, femoral strength increased more with teriparatide than alendronate for a given peripheral BMD change.
In plain wordsComputer estimates showed more thighbone strength gain with teriparatide than alendronate for the same peripheral density change.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEstimated femoral strength conditional on peripheral BMD
Study
n = 48
Non-linear finite element analysis of QCT scans under a simulated sideways fall
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
related, we also found that, for a given change in peripheral volumetric BMD, femoral strength increased more for teriparatide than for alendronate (p=0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2201581807
08Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoEfficacy outcome
In scan-based simulations, overall femoral strength changes did not differ significantly between teriparatide and alendronate.
In plain wordsComputer estimates showed no significant difference in overall thighbone strength changes between teriparatide and alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOverall estimated femoral strength change versus alendronate
Study
n = 48
Non-linear finite element analysis of QCT scans under a simulated sideways fall
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The only significant between-treatment difference was in the change in trabecular volumetric BMD (p<0.005);
2 context sentences(design, population, supporting numbers)
Summary · context
The QCT scans, obtained at baseline, 6, and 18 months, were analyzed for volumetric bone mineral density (BMD) of trabecular bone, the peripheral bone (defined as all the cortical bone plus any endosteal trabecular bone within 3 mm of the periosteal surface), and the integral bone (both trabecular a…
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2201581810
09Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoEfficacy outcome
In simulations from osteoporotic women's scans, estimated femoral strength did not significantly change after teriparatide versus baseline.
In plain wordsComputer estimates showed no significant change in thighbone strength after teriparatide compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeEstimated femoral strength
Study
n: not reported in source
Non-linear finite element analysis of QCT scans under a simulated sideways fall
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
integral volumetric BMD (+1.0%, p=0.38) and femoral strength (+5.4%, p=0.06) did not change significantly,
2 context sentences(design, population, supporting numbers)
Summary · context
The QCT scans, obtained at baseline, 6, and 18 months, were analyzed for volumetric bone mineral density (BMD) of trabecular bone, the peripheral bone (defined as all the cortical bone plus any endosteal trabecular bone within 3 mm of the periosteal surface), and the integral bone (both trabecular a…
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2201581804
10Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoEfficacy outcome
In simulations from osteoporotic women's scans, the strength-to-density ratio increased after teriparatide versus baseline.
In plain wordsComputer estimates showed a higher bone strength-to-density ratio after teriparatide compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEstimated strength to integral BMD ratio
Study
n: not reported in source
Non-linear finite element analysis of QCT scans under a simulated sideways fall
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Ratio change
4%
teriparatide versus baseline
Source sentences
Summary
but the ratio of strength to integral volumetric BMD ratio increased (+4.0%, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treat…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2201581805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.